Endpoints used in phase III randomized controlled trials of treatment options for COVID-19.
作者信息
Desai Aakash, Gyawali Bishal
机构信息
Deparment of Medicine, University of Connecticut, Farmington, CT 06030, United States.
Department of Oncology, Queen's University, Kingston, Canada.
出版信息
EClinicalMedicine. 2020 Jun 2;23:100403. doi: 10.1016/j.eclinm.2020.100403. eCollection 2020 Jun.
Abstract
摘要
相似文献
1
Endpoints used in phase III randomized controlled trials of treatment options for COVID-19.用于COVID-19治疗方案的III期随机对照试验中的终点指标。
EClinicalMedicine. 2020 Jun 2;23:100403. doi: 10.1016/j.eclinm.2020.100403. eCollection 2020 Jun.
2
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.生活质量评估和报告在结直肠癌中的应用：2012 年至 2018 年发表的 III 期临床试验的系统评价。
Crit Rev Oncol Hematol. 2020 Feb;146:102877. doi: 10.1016/j.critrevonc.2020.102877. Epub 2020 Jan 18.
3
How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.如何使用 frailtypack 验证来自随机对照试验荟萃分析的个体患者数据的失效时间替代终点。
PLoS One. 2020 Jan 28;15(1):e0228098. doi: 10.1371/journal.pone.0228098. eCollection 2020.
4
Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer.未达到主要终点的可能原因：对非小细胞肺癌患者的随机对照3期临床试验的系统评价
Ther Innov Regul Sci. 2019 May;53(3):324-331. doi: 10.1177/2168479018791135. Epub 2018 Aug 8.
5
Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.审查新 FDA 终点的偏头痛急性治疗试验结果：对未来试验的设计影响。
Headache. 2019 May;59(5):819-824. doi: 10.1111/head.13511. Epub 2019 Apr 6.
6
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.所有芳香化酶抑制剂都一样吗？乳腺癌对照临床试验综述。
Clin Ther. 2005 Nov;27(11):1671-84. doi: 10.1016/j.clinthera.2005.11.013.
7
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.一种用于肿瘤学试验的适应性无缝II/III期设计，该设计使用相关生存终点进行亚组选择。
Pharm Stat. 2011 Jul-Aug;10(4):347-56. doi: 10.1002/pst.472. Epub 2010 Dec 8.
8
Surrogate endpoints in randomized cardiovascular clinical trials.随机心血管临床试验中的替代终点。
Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4.
9
Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.基于图像的优化替代终点在胶质母细胞瘤靶向治疗中的应用：III 期随机对照临床试验的系统评价和荟萃分析。
Korean J Radiol. 2020 Apr;21(4):471-482. doi: 10.3348/kjr.2019.0839.
10
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.其他范例：更好的试验能识别更好的治疗方法：随机 II 期研究的价值。
Cancer J. 2009 Sep-Oct;15(5):426-30. doi: 10.1097/PPO.0b013e3181b9c5d5.
引用本文的文献
1
Lessons from the PROTECT-CH COVID-19 platform trial in care homes.来自护理院PROTECT-CH COVID-19平台试验的经验教训。
Health Technol Assess. 2025 Apr 9:1-26. doi: 10.3310/MTRS8833.
2
Blood Transfusion Utilization in Patients with Severe Coronavirus Disease 2019 in the Republic of Korea: A Nationwide Population-Based Study.韩国2019年冠状病毒病重症患者的输血利用情况：一项基于全国人口的研究。
J Clin Med. 2024 Dec 2;13(23):7327. doi: 10.3390/jcm13237327.
3
Mechanisms and Assessment of Genotoxicity of Metallic Engineered Nanomaterials in the Human Environment.人类环境中金属工程纳米材料的遗传毒性机制与评估
Biomedicines. 2024 Oct 20;12(10):2401. doi: 10.3390/biomedicines12102401.
4
Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.从临床样本中优化 SARS-CoV-2 的培养用于临床试验申请。
mSphere. 2024 Nov 21;9(11):e0030424. doi: 10.1128/msphere.00304-24. Epub 2024 Oct 16.
5
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).门诊环境下口服贝米福韦（AT-527）与安慰剂治疗轻至中度新冠肺炎患者的疗效对比（MORNINGSKY研究）
Future Virol. 2023 Oct. doi: 10.2217/fvl-2023-0115. Epub 2023 Nov 1.
6
Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?阿那白滞素被批准用于治疗重症2019冠状病毒病；是脓毒症的突破还是反思的时候了？
Front Microbiol. 2023 Oct 19;14:1250483. doi: 10.3389/fmicb.2023.1250483. eCollection 2023.
7
Quantifying the Neuropsychiatric Symptoms in Post-Acute Sequelae of COVID-19 (PASC) using the NIH Toolbox and PROMIS.使用美国国立卫生研究院工具包和患者报告结果测量信息系统（PROMIS）对新冠后急性后遗症（PASC）中的神经精神症状进行量化。
NeuroImmune Pharm Ther. 2023 Jun 20;2(2):95-101. doi: 10.1515/nipt-2022-0010. Epub 2022 Aug 15.
8
Abnormal brain diffusivity in participants with persistent neuropsychiatric symptoms after COVID-19.新冠病毒感染后持续存在神经精神症状的参与者脑扩散异常
NeuroImmune Pharm Ther. 2023 Mar 25;2(1):37-48. doi: 10.1515/nipt-2022-0016. Epub 2023 Jan 5.
9
Maternal and Neonatal Outcomes in Pregnant Women With Coronavirus Disease 2019 in Korea.韩国 2019 冠状病毒病孕妇的母婴结局。
J Korean Med Sci. 2022 Oct 24;37(41):e297. doi: 10.3346/jkms.2022.37.e297.
10
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial.ELOM-080 作为附加疗法治疗急性呼吸功能不全的 COVID-19 患者的疗效和安全性：来自前瞻性安慰剂对照 COVARI 试验的探索性数据。
Adv Ther. 2022 Jun;39(6):3011-3018. doi: 10.1007/s12325-022-02135-z. Epub 2022 Apr 13.
本文引用的文献
1
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
2
Drug Evaluation during the Covid-19 Pandemic.新冠疫情期间的药物评估
N Engl J Med. 2020 Jun 11;382(24):2282-2284. doi: 10.1056/NEJMp2009457. Epub 2020 Apr 14.
Zotero 插件